| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.09 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.09 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.1 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | selumetinib:JQ-1 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.066 | 0.1 |